论文部分内容阅读
罗氏制药公司近日宣布,2035例此前未经治疗的转移性直肠癌患者被征集参加大型国际第Ⅲ期试验(NO16966)达到两个主要终点的要求。在无进展生存期(PFS,指在疾病无进展的情况下患者的生存时间)方面,试验结果表明希罗达(Xeloda,亦即卡培他滨-Capecitabine)结合奥沙利铂(Oxaliplatin)的XELOX化疗法的效果等同于注射5-氟尿嘧啶(5-FU)/亚叶酸(leucovorin)结合奥沙利铂的FOLFOX疗法。与单一化疗法相比,FOLFOX与XELOX中加入贝伐单抗(bevaci-zumab,亦即阿瓦斯丁-Avastin)可极大地提高无进展生存期。
Roche Pharmaceuticals recently announced that 2035 patients with previously untreated metastatic colorectal cancer have been recruited to meet the requirements of the two major end-points for the large International Phase III trial (NO16966). In Progression Free Survival (PFS), which refers to the patient’s survival time in the absence of disease, test results show that Xeloda (ie capecitabine-Capecitabine) binds to oxaliplatin The effect of XELOX chemotherapy is equivalent to FOLFOX therapy with 5-fluorouracil (5-FU) / leucovorin in combination with oxaliplatin. Addition of bevaci- zumab (Avastin-Avastin) to FOLFOX and XELOX significantly improves progression-free survival compared to monotherapy.